TABLE I.
Demographic and Pharmacologic Characteristics of the Study Population, by Aortic Valve Regurgitation Status
| No. % | ||||
|---|---|---|---|---|
| Characteristic | Total (N = 113) | Improved aortic valve regurgitation (n = 38) | No change (n = 75) | P valuea |
| Age, mean (SD), y | 64.7 (9.9) | 63.6 (11.6) | 65.3 (8.9) | .39 |
| Sex | .04 | |||
| Male | 35 (31.0) | 7 (18.4) | 28 (37.3) | |
| Female | 78 (69.0) | 31 (81.6) | 47 (62.7) | |
| Diabetes | 35 (31.0) | 11 (28.9) | 24 (32.0) | .74 |
| Hypertension | 78 (69.0) | 25 (65.8) | 53 (70.7) | .59 |
| Dyslipidemia | 56 (49.6) | 14 (36.8) | 42 (56.0) | .05 |
| Cigarette smoking status | 31 (27.4) | 12 (31.6) | 19 (25.3) | .48 |
| Family history of aortic valve regurgitation | 28 (24.8) | 12 (31.6) | 16 (21.3) | .23 |
| Diuretic use | 41 (36.3) | 15 (39.5) | 26 (34.7) | .61 |
| Angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker use | 77 (68.1) | 28 (73.7) | 49 (65.3) | .36 |
| Nitrate use | 82 (72.6) | 24 (63.2) | 58 (77.3) | .11 |
| Statin use | 98 (86.7) | 35 (92.1) | 63 (84.0) | .23 |
a
A 2-sided P < .05 was regarded as statistically significant.